| This week's sponsor is FierceBiotech Drug Development Forum. | |  | FierceBiotech 2nd Drug Development Forum - September 25-27 in Boston
90+ executive-level speakers share advanced partnership and pipeline strategies. Learn to adapt to increased deal complexity, real world evidence and digital technologies. Unequaled networking! Sign up by August 11 to save $200 on registration. |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, July 18, 2017 Hundreds of Takeda employees in R&D and vaccines have been asked to relocate from suburban Chicago to the Boston area as part of a two-year effort to position its U.S. jobs in the vibrant scientific hub, according to a new report. |
|
|
Top Stories Of The Week Monday, July 17, 2017 The FDA has rejected Amgen’s application for approval of osteoporosis candidate romosozumab. Officials knocked back the filing after phase 3 data linked the sclerostin-targeting antibody to an increased risk of cardiovascular adverse events. Monday, July 17, 2017 Unless you’ve been on vacation in the Amazon, you’ve heard the reports: AstraZeneca CEO Pascal Soriot was said to have signed on as the new chief at Teva. Friday, though, AZ said Soriot would be around to lead its July 27 earnings call. It appeared to be a nonconfirmation confirmation that he’s staying put. We have some theories. Wednesday, July 19, 2017 Vertex’s triple combination cystic fibrosis regimens have aced early-phase clinical trials. The strong efficacy seen in the trials suggests the combinations can treat most cystic fibrosis patients, opening the door to an expanded multibillion-dollar market. Wednesday, July 19, 2017 GlaxoSmithKline is looking to unload some marginal businesses and make other cuts that it says will cost about 320 manufacturing jobs in its home country over the next three years. In addition, the company is canceling plans to build a new biologics plant that would have resulted in about 500 new jobs. Monday, July 17, 2017 Diagnostics maker Quidel has penned a deal to acquire Alere’s triage assets as it boosts its position in the point-of-care market, as well as its geographic footprint. Wednesday, July 19, 2017 What can Alexa do for diabetes patients? A virtual coach might sense a patient's mood. An AI platform could detect risky behavior. Or the Amazon assistant could help assess nutrition and plan meals. These are three of the top answers Merck & Co. netted when it posed that question to enterprising techies. Monday, July 17, 2017 Scientists at the University of Pennsylvania have discovered three genetic variants that may enhance the immune system’s ability to fight Alzheimer’s—and that may be targetable with drugs. The variants are found in microglia, brain cells that surround amyloid plaques found in the brains of patients. Friday, July 14, 2017 After taking a beating in countless press reports over its Zika vaccine partnership with the U.S. Army, Sanofi is hoping to clear the air with a flurry of letters to critical U.S. senators. Thursday, July 20, 2017 Sarepta is offering its Duchenne therapy Exondys 51 in certain countries outside of the U.S. through a compassionate use program managed by Clinigen, as the company reported better-than-expected revenues from the medication in the U.S. and as the EMA is still evaluating the drug in due process. | This week's sponsor is Cardinal Health. | |  | [Webinar] Accelerating Clinical Trials through Adaptive Designs
Thursday, August 3 | 2pm ET / 11am PT
Early-phase adaptive clinical trials help companies accelerate product development by combining multiple clinical objectives into one study to deliver high-quality data and substantial time and cost savings. This interactive webinar will provide the framework for scientifically robust and efficient early-phase clinical drug development. Reserve Your Spot Today! |
|
|
